1st Circ. Denies Bid To Stall Solodyn Pay-For-Delay Trial
Law360 (February 13, 2018, 8:26 PM EST) -- The First Circuit on Monday denied an attempt by Valeant Pharmaceuticals subsidiary Medicis Pharmaceutical Corp. to stall a March trial slated to decide whether the company paid generic-drug makers to stay out of the market for acne medication Solodyn.
Coupled with Medicis’ losses at the summary judgment phase last month, the multidistrict litigation from customers and retailers, including Walgreen Co., CVS Pharmacy Inc. and Rite-Aid Corp., alleging anti-competitive practices surrounding Solodyn is set to go to a jury on March 12 barring any eleventh-hour settlements.
“We conclude that the requirements for interlocutory review of class certification determinations have not been met...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!